| 000 | 01669 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516082620.0 | ||
| 264 | 0 | _c20120816 | |
| 008 | 201208s 0 0 eng d | ||
| 022 | _a1815-7920 | ||
| 024 | 7 |
_a10.5588/ijtld.11.0376 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYee, D P | |
| 245 | 0 | 0 |
_aClinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. _h[electronic resource] |
| 260 |
_bThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease _cMay 2012 |
||
| 300 |
_a604-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntitubercular Agents _xpharmacology |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDrug Resistance, Bacterial |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 |
_aPyrazinamide _xpharmacology |
| 650 | 0 | 4 | _aQuebec |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTuberculosis _xdrug therapy |
| 700 | 1 | _aMenzies, D | |
| 700 | 1 | _aBrassard, P | |
| 773 | 0 |
_tThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease _gvol. 16 _gno. 5 _gp. 604-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5588/ijtld.11.0376 _zAvailable from publisher's website |
| 999 |
_c21615045 _d21615045 |
||